BIOS Memory SPV I, LP
Known title: 10% OwnerCIK: 0001643749
BIOS Memory SPV I, LP's purchase track record
BIOS Memory SPV I, LP has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/13/2021 | CGTX | $2.28M | -48.7% | -76.4% | +1.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CGTX | ▼ Sell | Other | 34,238 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 24,263 | — | 10/13/2021 | View on chart |
| CGTX | ▲ Buy | Open Market | 23,341 | $280K | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 351,844 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 33,495 | $1K | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Open Market | 90 | $1K | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 41,620 | — | 10/13/2021 | View on chart |
| CGTX | ▲ Buy | Open Market | 22,129 | $266K | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 596,899 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 158,476 | — | 10/13/2021 | View on chart |
| CGTX | ▲ Buy | Open Market | 144,530 | $1.7M | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 34,472 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 25,593 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 418,926 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 245,029 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 78,298 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 255,765 | — | 10/13/2021 | View on chart |
| CGTX | ▼ Sell | Other | 1,424,014 | — | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.